We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The price of U.S. cancer drugs keeps climbing despite market competition, while the costs of the same drugs have stayed relatively flat or have actually decreased in Germany and Switzerland. Read More
The U.S. government is pulling GlaxoSmithKline’s and Vir Technology’s investigational monoclonal antibody for COVID-19 from certain states where cases of the new subvariant of Omicron, BA.2, are high, as tests have shown that the treatment isn’t effective against the new strain. And the FDA has amended sotrovimab’s Emergency Use Authorization (EUA) accordingly. Read More
Novo Nordisk has settled a patent dispute with Novartis over allegations that the Swiss company infringed on patents for Victoza (liraglutide), Novo Nordisk’s blockbuster type 2 diabetes drug. Read More
Takeda Pharmaceuticals has received a Complete Response Letter from the FDA denying its Prior Approval Supplement (PAS) application for Natpara (parathyroid hormone) for chronic hypoparathyroidism. Read More
After 14 years of legal wrangling over Fosamax’s bone-fracture risk, Merck has managed to get a federal judge to dismiss in excess of 500 lawsuits charging the drugmaker with staying silent about the dangerous and painful leg breaks the osteoporosis drug was allegedly known to cause. Read More
Just hours before it was to face the start of a trial, Sun Pharmaceuticals of India said it will pay $485 million to settle years-old lawsuits alleging its Ranbaxy Pharmaceuticals subsidiary falsified data to hoodwink the FDA into granting exclusive approvals for its generic drugs, thus delaying competition and making people pay exorbitant prices for the generics. Read More
A coalition of advocacy groups has appealed to Health and Human Services Secretary Xavier Becerra to act unilaterally to lower the prices of six prescription drugs using an obscure and controversial regulatory authority known as “march-in rights.” Read More